Home > Insider Trading > Filing (0001209191-14-018505)

Filing Details

Accession Number:: 0001209191-14-018505
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-07 18:20:51
Reporting Period:: 2014-03-05

Filing Date:: 2014-03-07
Accepted Time:: 2014-03-07 18:20:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581992	Glenn Goddard	C/O Agios Pharmaceuticals, Inc. 38 Sidney Street, 2Nd Floor Cambridge MA 02139	Senior Vice President, Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-03-06	5,468	$0.47	5,468	No	4	M	Direct
Common Stock	Disposition	2014-03-06	5,468	$35.54	0	No	4	S	Direct
Common Stock	Acquisiton	2014-03-07	9,666	$0.47	9,666	No	4	M	Direct
Common Stock	Acquisiton	2014-03-07	2,334	$0.69	12,000	No	4	M	Direct
Common Stock	Disposition	2014-03-07	12,000	$45.10	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Acquisiton	2014-03-05	40,000	$0.00	40,000	$31.64
Common Stock	Stock option (right to buy)	Disposition	2014-03-06	5,468	$0.00	5,468	$0.47
Common Stock	Stock option (right to buy)	Disposition	2014-03-07	9,666	$0.00	9,666	$0.47
Common Stock	Stock option (right to buy)	Disposition	2014-03-07	2,334	$0.00	2,334	$0.69

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
135,739	2024-03-04	No	4	A	Direct
130,271	2020-08-11	No	4	M	Direct
120,605	2020-08-11	No	4	M	Direct
118,271	2021-09-14	No	4	M	Direct

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $35.00 to $36.86. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $45.00 to $46.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
This option was granted on August 12, 2010. The shares underlying this option vest as to 25% of the underlying shares on July 1, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.
This option was granted on September 15, 2011. The shares underlying this option vest as to 25% of the underlying shares on September 15, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter.